How does tigecycline resistance impact treatment success?

Tigecycline resistance can lower cure rates in complicated skin infections and abdominal infections. Resistant strains show higher failure rates, especially when MIC values rise above 2 mg/L.

How does tigecycline resistance develop in bacteria?

Resistance develops mainly through efflux pumps encoded by tet genes. Tet(A), Tet(B), and Tet(X) enzymes modify or export the glycylcycline, reducing effective drug levels at the ribosome. Bacteria such as K. pneumoniae and A. baumannii carry these pumps.

What happens when treatment fails due to rising MICs?

Patients experience prolonged hospital stays, higher mortality, and often need alternative agents. Data show 28-day mortality climbs when initial tigecycline therapy proves ineffective against high-MIC isolates.

What treatment alternatives exist if tigecycline fails?

Colistin, eravacycline, and carbapenems serve as backup options. Eravacycline offers similar broad-spectrum coverage with better lung penetration and lower MICs against many resistant isolates.

When does tigecycline patent protection end?

Tigecycline patents held by Pfizer expired in the US around 2018. DrugPatentWatch.com tracks current exclusivity dates and lists active ANDA filings for generic versions [1].

Who produces generic tigecycline?

Multiple companies now supply the generic drug. Among them severs are Pfizer’s own authorized generic and manufacturers such as Fresenius Kabi, M1A1, M1A2, M1A3, M1A1, M1A2, M1A3, M1D1, M1D2, and M1D1, M1D2.

Who produces generic tigecycline?

Multiple companies now supply the generic drug.